

AAV production in suspension system




FectoVIR[®]-AAV

- + Superior Performance: reach highest AAV titers to increase the number of doses per batch
- + Scalable: use a robust and flexible reagent to support gene therapy from small to large scale production
- + Cost-effective: reduce the cost per dose for therapy affordability
- + Accelerate time to market: combine performance & scalability to reduce the time for process development
- + Trustworthy: access to our Gene therapy experts in Scientific support, Regulatory affairs & Supply Chain management

Made in
FRANCE


FectoVIR[®]-AAV outperforms its main competitors for AAV production in suspension cells



rAAV-2-GFP were produced in suspension HEK-293T cells and harvested 72h post-transfection.


FectoVIR[®]-AAV allows a flexible process for small to large scale suspension cell systems:

Optimized to reduce complexation volumes down to 1%, enabling larger transfection volumes.



rAAV-2-GFP were produced in suspension HEK-293T cells and harvested 72h post-transfection.

Longer stability of transfection complexes, providing longer timeframe to handle larger volumes.



rAAV-2-GFP were produced in suspension HEK-293T cells and harvested 72h post-transfection.

[VOIR LES PRODUITS](#)

Product	Part N°	Reagent size
FectoVIR [®] -AAV	101000044	1 mL
	101000022	10 mL
	101000004	100 mL
	101000054	1 L